Do Dose Response Relationship Is Flat for Hyperkalemia

Three large scale placebo control trials with mineralylcorticoid receptor antagonist, sprylylactone and a pleuronone that show a reduction in major heartfarer events. In all three trials they found that patients had a benefit when they were up titrated to low doses. The lower dose works just as well as the higher dose and produces much less hyperkalemia. But what physicians do very commonly is they don't reduce the dose, they stop the drug complete.